drugset / Trial / NCT06176729
Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients
Phase 2
Recruiting
30 enrolled
Yan Zhang, MD
Chinese PLA General Hospital · collabPeking University First Hospital · collabPeking University Third Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-arm, phase II study, and the purpose of this study is to evaluate the efficacy and safety of Pola-R2 regimen in newly diagnosed elderly diffuse large B cell lymphoma classified into un-fit or frail group by comprehensive geriatric assessment(CGA).
Timeline
- Start
- 2023-10-24
- Primary completion
- 2025-10-24
- Completion
- 2027-10-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 25 mg | Oral |
| Subject | Polatuzumab Vedotin | Other / unclassified | 1.8 mg/kg | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |